Brought to you by 
Human Longevity closes $220mm Series B round
Apr 2016
Executive Summary
Human Longevity Inc. (HLI) raised $220mm through its Series B round from investors including Illumina, Celgene, GE Ventures, and buyers from the firm's Series A round (which closed at $80mm late last year). The company, which is creating a database of whole genome, phenotype, and clinical data for therapeutic and diagnostic use, will put the Series B money towards expansion of its products, including supporting HLI's first Health Nucleus division, a genomic enhanced health center, and growing HLI's Knowledgebase of genomic and phenotypic data.
Deal Industry
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- In Vitro Diagnostics
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
- Services
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Human Longevity closes $220mm Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice